Real World Effectiveness of Capmatinib in Patients With Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU)
Latest Information Update: 21 Oct 2022
At a glance
- Drugs Capmatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CapmATU
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
- 24 Feb 2022 Status changed from recruiting to completed.
- 15 Dec 2021 New trial record